We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.39%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.34B
AUM Growth
+$471M
Cap. Flow
+$471M
Cap. Flow %
20.11%
Top 10 Hldgs %
49.6%
Holding
148
New
13
Increased
17
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$59.2M
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$51.5M
3
SWTX
SpringWorks Therapeutics
SWTX
+$33.1M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$25.3M
5
KLRS
Kalaris Therapeutics
KLRS
+$22M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$92.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$87.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$28.5M
4
CYTK icon
Cytokinetics
CYTK
+$13.2M
5
BLU
BELLUS Health Inc.
BLU
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 77.68%
2 Consumer Discretionary 2.9%
3 Financials 0.65%
4 Consumer Staples 0.17%
5 Industrials 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRVS icon
126
Corvus Pharmaceuticals
CRVS
$1.1B
$409K 0.02%
500,000
– –
LITS
127
Lite Strategy Inc
LITS
$32.4M
$387K 0.02%
50,000
– –
APLT
128
DELISTED
Applied Therapeutics
APLT
$372K 0.02%
400,000
– –
ADBE icon
129
Adobe
ADBE
$105B
$358K 0.02%
+1,300
New +$492K
KA
130
DELISTED
Kineta, Inc. Common Stock
KA
$341K 0.01%
31,056
– –
ATXS
131
DELISTED
Astria Therapeutics
ATXS
$301K 0.01%
33,333
– –
CFRX
132
DELISTED
ContraFect Corporation
CFRX
$252K 0.01%
18,750
– –
CDAK
133
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$156K 0.01%
200,000
– –
CDTX
134
DELISTED
Cidara Therapeutics
CDTX
$141K 0.01%
11,234
– –
SGTX
135
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$139K 0.01%
21,231
– –
ADVM
136
DELISTED
Adverum Biotechnologies
ADVM
– –
-300,000
Closed -$3.6M
ALNY icon
137
Alnylam Pharmaceuticals
ALNY
$38.1B
– –
-600,000
Closed -$87.5M
AMLX icon
138
Amylyx Pharmaceuticals
AMLX
$2.13B
– –
-75,000
Closed -$1.45M
ATRA icon
139
Atara Biotherapeutics
ATRA
$69.8M
– –
-40,000
Closed -$7.79M
BBWI icon
140
Bath & Body Works
BBWI
$3.96B
– –
-12,500
Closed -$337K
C icon
141
CALL
Citigroup
C
$215B
– –
-1,000,000
Closed -$46M
CLF icon
142
Cleveland-Cliffs
CLF
$6.35B
– –
-25,000
Closed -$384K
DSGN icon
143
Design Therapeutics
DSGN
$741M
– –
-400,000
Closed -$5.6M
IVVD icon
144
Invivyd
IVVD
$163M
– –
-1,000,000
Closed -$3.28M
LABU icon
145
CALL
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$508M
– –
-200,000
Closed -$27M
UNG icon
146
United States Natural Gas Fund
UNG
$450M
– –
-5,000
Closed -$380K
CINC
147
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-137,010
Closed -$2.58M
KLDO
148
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
– –
-500,500
Closed -$31K
2 3 4 5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2022 Portfolio in Review

As of Q3 2022, Artal Group held 148 positions worth $2.34B, up 25% from $1.87B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group deployed $471M of net new capital in Q3 2022, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 89% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was argenx, an estimated $92.6M trimmed.

  • Artal Group's largest Q3 2022 buy was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q3 2022, an estimated $51.5M increase.
  • Artal Group's biggest Q3 2022 reduction was argenx, cutting an estimated $92.6M.
  • Artal Group fully exited Alnylam Pharmaceuticals in Q3 2022, selling an estimated $87.5M.
  • Artal Group's ten largest holdings make up 50% of its $2.34B portfolio in Q3 2022.
  • Artal Group opened 13 new positions and closed 13 in Q3 2022.
  • Artal Group's portfolio value rose 25% quarter-over-quarter to $2.34B.

Based on Artal Group's 13F filing for Q3 2022, filed 14 Nov 2022.